drugset / Trial / NCT01319383

The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART

NCT01319383

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to compare HIV RNA expression and infection within resting (CD4)+ cells in HIV-infected patients on stable ART before and after a single exposure to Vorinostat (VOR), after exposure to short intervals of VOR, and after repeated short interval exposure to VOR dosed over several weeks. Hypotheses: 1. The frequency of resting CD4+ T cell- associated HIV RNA (RCVL) will be increased following single and repeated exposure to VOR when given at appropriate intervals, and 2. That repeated exposure to VOR will reduce the frequency of HIV infection within resting CD4+ T cells (RCI)

Timeline

Start
2011-02
Primary completion
2016-03-31
Completion
2016-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Vorinostat Small molecule 400 mg Oral